Is Invivyd, Inc. (IVVD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 13.7% / 30% | 2.2% / 30% | 27.38% / 5% | ✗ NOT HALAL |
| DJIM | 0.3% / 33% | 13.7% / 33% | 2.2% / 33% | 27.38% / 5% | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 53.5% / 33% | 8.6% / 33% | 27.38% / 5% | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 13.7% / 33% | 2.2% / 33% | 27.38% / 5% | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 53.5% / 33% | 8.6% / 50% | 27.38% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 93.0% | |
| Operating Margin | -73.0% | |
| Net Margin | -98.2% | |
| Return on Equity (ROE) | -34.0% | |
| Return on Assets (ROA) | -17.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$58M |
| Free Cash Flow | -$58M |
| Total Debt | $2M |
| Debt-to-Equity | 1.0 |
| Current Ratio | 7.2 |
| Total Assets | $277M |
Price & Trading
| Last Close | $1.51 |
| 50-Day MA | $1.75 |
| 200-Day MA | $1.55 |
| Avg Volume | 2.9M |
| Beta | 0.6 |
|
52-Week Range
$0.46
| |
About Invivyd, Inc. (IVVD)
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Invivyd, Inc. (IVVD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Invivyd, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Invivyd, Inc.'s debt ratio?
Invivyd, Inc.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Invivyd, Inc.'s key financial metrics?
Invivyd, Inc. has a market capitalization of $387M, and revenue of $53M. The company maintains a gross margin of 93.0% and a net margin of -98.2%. Return on equity stands at -34.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.